tiprankstipranks
Trending News
More News >
Scancell Holdings (GB:SCLP)
:SCLP
Advertisement

Scancell Holdings (SCLP) AI Stock Analysis

Compare
19 Followers

Top Page

GB:SCLP

Scancell Holdings

(LSE:SCLP)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
Scancell Holdings' overall stock score is heavily influenced by its poor financial performance, characterized by zero revenue and significant losses. However, recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a mixed trend with short-term bullish momentum, though overbought conditions warrant caution. Valuation remains unattractive, reflecting ongoing financial challenges. Overall, while there are promising developments in the pipeline, the company’s current financial challenges necessitate caution.

Scancell Holdings (SCLP) vs. iShares MSCI United Kingdom ETF (EWC)

Scancell Holdings Business Overview & Revenue Model

Company DescriptionScancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
How the Company Makes MoneyScancell Holdings makes money primarily through the development and commercialization of its immunotherapy technologies. The company's revenue model includes licensing agreements with pharmaceutical and biotechnology companies, where Scancell grants rights to develop and market its therapeutic products in exchange for upfront payments, milestone payments, and royalties on sales. Additionally, Scancell may receive funding from research grants and partnerships with academic institutions that support the advancement of its technology platforms. These collaborations and partnerships are significant contributors to the company's earnings, helping to finance ongoing research and development activities.

Scancell Holdings Earnings Call Summary

Earnings Call Date:Sep 11, 2025
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Jan 29, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook with significant advancements in product development, regulatory submissions, and strategic partnerships. Financial positioning is bolstered by recent fundraising and revenue from licensing agreements. However, increased R&D expenses and operating loss highlight ongoing financial challenges. Overall, the company's progress and potential overshadow the financial concerns.
Q4-2025 Updates
Positive Updates
Partnership with Cancer Vaccine Launch Pad
Formed a major partnership with the cancer vaccine Launch Pad, highlighting strategic alliances.
iSCIB1+ Progression-Free Survival (PFS) Advantage
iSCIB1+ shows a PFS of 78% in advanced melanoma, compared to 46% for standard care.
Regulatory and Manufacturing Advancements
Documentation submitted to FDA and other regulators for iSCIB1+. Commercial-scale manufacturing process confirmed.
GlyMab Therapeutics Establishment
Established GlyMab Therapeutics, providing strategic optionality for antibody development.
Financial Position and Funding
Raised GBP 12.1 million in financing, ensuring a strong financial position moving forward.
Revenue from Genmab Licensing Agreement
Reported revenues of GBP 4.7 million from Genmab licensing, with potential for further milestone payments.
Modi-1 and GlyMab Assets Development
Progress in ModiFY study for Modi-1 in head and neck cancer, and GlyMab assets poised for further development.
Negative Updates
Research and Development Expenses Increase
R&D expenses increased to GBP 14.7 million, reflecting higher expenditure on clinical and manufacturing costs.
Operating Loss
Operating loss of GBP 15 million, although lower than the previous year, still presents a financial challenge.
Convertible Loan Notes
Convertible loan notes were extended, totaling GBP 18.2 million, indicating ongoing financial obligations.
Company Guidance
During the call, Scancell Holdings plc provided comprehensive guidance on its financial and operational progress for the fiscal year ended April 30, 2025. Key metrics highlighted include a reported revenue of GBP 4.7 million, largely attributed to their second commercial license agreement with Genmab, which included upfront payments totaling USD 6 million and potential further milestone payments up to $630 million. The company also successfully raised GBP 12.1 million in late 2024, strengthening its financial position with a cash reserve of GBP 16.9 million as of year-end. Research and development expenses were GBP 14.7 million, focusing on their SCOPE and MODIFY studies. The company anticipates a tax credit of approximately GBP 3 million, contributing to an operating loss of GBP 15 million. Scancell is optimistic about its cash runway extending into the second half of 2026, thanks to the recent financing and potential upside from future Genmab milestone payments. The company is poised for advanced regulatory discussions and aims to initiate randomized studies for iSCIB1+ in 2026, underlining a clear pathway toward commercialization and potential partnerships.

Scancell Holdings Financial Statement Overview

Summary
Scancell Holdings is facing severe financial challenges characterized by zero revenue, consistent losses, and a highly leveraged balance sheet. The negative cash flow situation compounds these issues, indicating that the company may struggle to sustain operations and finance future growth without significant changes or infusions of capital. Caution is advised due to the high-risk financial profile.
Income Statement
10
Very Negative
Scancell Holdings has faced significant challenges in generating revenue, with zero revenue reported in the most recent period. The company has consistently operated at a loss with a negative net income and gross profit, indicating weak profitability. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. The lack of revenue growth highlights the company's struggle to penetrate or expand its market presence.
Balance Sheet
20
Very Negative
The company's balance sheet reveals a concerning financial structure, with negative stockholders' equity indicating potential solvency issues. The debt-to-equity ratio cannot be calculated due to negative equity, but high total debt relative to total assets suggests significant leverage. The equity ratio is negative, signaling that liabilities exceed assets. This poses substantial risk to financial stability and could limit future financing options.
Cash Flow
15
Very Negative
Scancell Holdings has experienced negative free cash flow, with a downward trend over the past years. The operating cash flow is negative, indicating that the company is not generating sufficient cash from operations to cover its expenses, let alone invest in growth. The free cash flow to net income ratio is not meaningful due to negative values, reflecting persistent cash flow challenges.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue0.004.71M0.005.27M0.000.00
Gross Profit-1.01M3.59M-966.00K4.75M-740.00K-249.00K
EBITDA-16.97M-12.71M-7.06M-12.19M-3.75M-14.90M
Net Income-15.81M-12.27M-5.86M-11.94M-2.06M-15.48M
Balance Sheet
Total Assets16.61M23.09M23.58M30.27M49.06M8.82M
Cash, Cash Equivalents and Short-Term Investments9.10M16.89M14.82M19.92M28.73M41.11M
Total Debt15.56M16.27M19.87M19.53M18.92M15.39M
Total Liabilities32.10M26.93M27.08M36.50M29.57M1.17M
Stockholders Equity-15.50M-3.83M-3.50M-6.23M18.11M19.48M
Cash Flow
Free Cash Flow-14.25M-6.12M-15.84M-8.34M-8.55M-4.80M
Operating Cash Flow-14.09M-6.11M-15.66M-8.14M-7.80M-4.77M
Investing Cash Flow-361.00K-1.54M178.00K81.00K-741.00K-13.00K
Financing Cash Flow10.54M9.73M10.39M-746.00K46.08M46.08M

Scancell Holdings Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price9.75
Price Trends
50DMA
9.98
Negative
100DMA
9.93
Negative
200DMA
9.64
Positive
Market Momentum
MACD
-0.02
Negative
RSI
50.40
Neutral
STOCH
42.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SCLP, the sentiment is Neutral. The current price of 9.75 is above the 20-day moving average (MA) of 9.58, below the 50-day MA of 9.98, and above the 200-day MA of 9.64, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 42.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:SCLP.

Scancell Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
£289.71M-73.02%
46
Neutral
£101.18M167.16%-85.29%
44
Neutral
£10.77M-333.59%45.22%55.71%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:SCLP
Scancell Holdings
9.75
-3.50
-26.42%
GB:AVCT
Avacta Group plc
71.00
20.50
40.59%
GB:IMM
ImmuPharma
11.10
9.21
487.30%
GB:OBD
Oxford BioDynamics
0.55
-3.23
-85.45%
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.40
-0.60
-30.00%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
1,165.00
647.80
125.25%

Scancell Holdings Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Scancell Partners with NHS to Fast-Track Melanoma Vaccine Access
Positive
Apr 14, 2025

Scancell Holdings has announced a partnership with the NHS Cancer Vaccine Launch Pad to fast-track access for NHS patients into the fourth cohort of its Phase 2 clinical SCOPE study. This study will evaluate the intradermal administration of Scancell’s iSCIB1+, a second-generation DNA cancer vaccine, in patients with advanced melanoma. This collaboration marks Scancell as the first British company to join the CVLP, and iSCIB1+ as the first DNA vaccine in this initiative. The partnership aims to expedite patient access to potentially life-saving treatments and accelerate the clinical development of Scancell’s novel cancer vaccine, which has shown promising efficacy and long-term survival benefits in early trials.

Spark’s Take on GB:SCLP Stock

According to Spark, TipRanks’ AI Analyst, GB:SCLP is a Neutral.

Scancell Holdings’ overall stock score is heavily weighted by its poor financial performance, which is characterized by zero revenue and significant losses. However, the recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a bearish trend, although the stock is nearing oversold territory, which might indicate a potential rebound. Valuation metrics remain unattractive due to ongoing financial losses. Overall, while there are promising developments in the pipeline, the company’s current financial challenges necessitate caution.

To see Spark’s full report on GB:SCLP stock, click here.

Product-Related AnnouncementsBusiness Operations and Strategy
Scancell to Present Promising Phase 2 Melanoma Vaccine Data at AACR 2025
Positive
Apr 1, 2025

Scancell Holdings has announced that it will present clinical data from its ongoing Phase 2 SCOPE trial of the SCIB1 melanoma vaccine at the 2025 AACR Annual Meeting. The trial, which investigates the use of SCIB1 in combination with checkpoint inhibitors for late-stage melanoma, has shown promising results with an 84% disease control rate and 80% progression-free survival. These findings underscore the potential of SCIB1 to transform melanoma treatment and will guide the design of a future global randomized control registration trial.

Executive/Board ChangesBusiness Operations and Strategy
Scancell Holdings Grants Share Options to Executive Directors
Neutral
Feb 20, 2025

Scancell Holdings plc has announced the issuance of share options to its executive directors as part of the company’s long-term incentive plan. The options, granted to CEO Phil L’Huillier, CSO Lindy Durrant, and CFO Sath Nirmalananthan, are intended to incentivize and retain key personnel. The options, which have an exercise price of 11.7 pence each, will vest over three years and represent a significant portion of the company’s issued share capital. This strategic move aims to align the interests of the executive team with those of shareholders and fortify Scancell’s positioning in the competitive biopharmaceutical industry.

Product-Related AnnouncementsBusiness Operations and Strategy
Scancell Presents Promising Phase 2 Data for Melanoma Vaccine at AACR IO Conference
Positive
Feb 17, 2025

Scancell Holdings plc announced that translational data from its ongoing Phase 2 SCOPE trial of SCIB1, a DNA plasmid melanoma cancer vaccine, will be presented at the AACR IO conference. The data showcases the efficacy of SCIB1 when combined with nivolumab and ipilimumab, demonstrating an 84% disease control rate and 80% progression-free survival in late-stage melanoma patients. This presentation is expected to validate SCIB1’s potential in cancer immunotherapy, potentially strengthening Scancell’s position in the industry and offering new hope for stakeholders, including patients and investors.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 23, 2025